6/28/23, 12:06 AM CHANCE-HF Pathway Feedback Search Clinical Topics Home Studies CHANCE HF CHANCE HF Disease Heart failure Trial question What is the role of carbohydrate antigen-125-guided therapy in patients with acute HF? Study design Multi-center Open label RCT Population Characteristics of study participants 44.0% female N = 380 56.0% male 380 patients (168 female, 212 male) Inclusion criteria: patients discharged for acute HF and high carbohydrate antigen-125 Key exclusion criteria: life expectancy < 12 months due to other diseases different from HF; pregnancy; angina pectoris higher than class II; VHD already scheduled for surgical intervention Interventions N=187 carbohydrate antigen-125-guided therapy (treatment measures aimed to keep carbohydrate antigen-125 35 U/mL) N=193 standard of care (therapy based on established European current guidelines) Primary outcome Death or acute heart failure readmission at 1 year, restricted mean survival time 0.7 years 0.74 0.66 0 6 https://web.pathway.md/studies/reci2bSLqXgwt6wBb 1/2 6/28/23, 12:06 AM 0.6 years CHANCE-HF Pathway 0.4 years 0.2 years Significant increase 0.0 years Carbohydrate antigen-125-guided therapy Standard of care Significant increase in death or acute HF readmission at 1 year, restricted mean survival time (0.74 years vs. 0.66 years; AD 0.08 years, 95% CI 0.02 to 0.15) Secondary outcomes No significant difference in death or any rehospitalization at 1 year, restricted mean survival time (0.67 years vs. 0.61 years; AD 0.054 years, 95% CI -0.02 to 0.13) No significant difference in the rate of death from all causes and days alive and out of the hospital (16.6% vs. 18.1%; HR 0.92, 95% CI 0.57 to 1.49) Significant decrease in the incidence of recurrent hospitalizations (0.67 events/person-year vs. 1.06 events/person-year; RR 0.63, 95% CI 0.5 to 0.8) Safety outcomes No significant differences in hospitalizations due to hyperkalemia, hypokalemia or acute renal failure. Conclusion In patients discharged for acute HF and high carbohydrate antigen-125, carbohydrate antigen- 125-guided therapy was superior to standard of care with respect to death or acute HF readmission at 1 year, restricted mean survival time. Reference Julio N ez, Pau Ll cer, Vicente Bertomeu-Gonz lez et al. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study. JACC Heart Fail. 2016 Nov;4(11):833-843. Open reference URL https://web.pathway.md/studies/reci2bSLqXgwt6wBb 2/2